BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 22581973)

  • 1. Prostate cancer risk assessment model: a scoring model based on the Swedish Family-Cancer Database.
    Roudgari H; Hemminki K; Brandt A; Sundquist J; Fallah M
    J Med Genet; 2012 May; 49(5):345-52. PubMed ID: 22581973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of bias in familial risk estimates: a study of common cancers using Swedish population-based registers.
    Leu M; Reilly M; Czene K
    J Natl Cancer Inst; 2008 Sep; 100(18):1318-25. PubMed ID: 18780865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates.
    Bratt O; Garmo H; Adolfsson J; Bill-Axelson A; Holmberg L; Lambe M; Stattin P
    J Natl Cancer Inst; 2010 Sep; 102(17):1336-43. PubMed ID: 20724726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing individual risk for prostate cancer.
    Nam RK; Toi A; Klotz LH; Trachtenberg J; Jewett MA; Appu S; Loblaw DA; Sugar L; Narod SA; Kattan MW
    J Clin Oncol; 2007 Aug; 25(24):3582-8. PubMed ID: 17704405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality.
    van Leeuwen PJ; van den Bergh RC; Wolters T; Zhu X; Bul M; Schröder FH; Bangma CH; Roobol MJ
    Can J Urol; 2011 Dec; 18(6):6018-24. PubMed ID: 22166329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial risks of breast and prostate cancers: does the definition of the at risk period matter?
    Brandt A; Bermejo JL; Sundquist J; Hemminki K
    Eur J Cancer; 2010 Mar; 46(4):752-7. PubMed ID: 20022238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer.
    Peters CA; Stock RG; Blacksburg SR; Stone NN
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):24-9. PubMed ID: 18692325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age at diagnosis and age at death in familial prostate cancer.
    Brandt A; Bermejo JL; Sundquist J; Hemminki K
    Oncologist; 2009 Dec; 14(12):1209-17. PubMed ID: 19939895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Family history of breast cancer as a predictor for fatal prostate cancer.
    Rodríguez C; Calle EE; Tatham LM; Wingo PA; Miracle-McMahill HL; Thun MJ; Heath CW
    Epidemiology; 1998 Sep; 9(5):525-9. PubMed ID: 9730031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial risk of cancer shortly after diagnosis of the first familial tumor.
    Bermejo JL; Hemminki K
    J Natl Cancer Inst; 2005 Nov; 97(21):1575-9. PubMed ID: 16264177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer.
    Tersmette AC; Petersen GM; Offerhaus GJ; Falatko FC; Brune KA; Goggins M; Rozenblum E; Wilentz RE; Yeo CJ; Cameron JL; Kern SE; Hruban RH
    Clin Cancer Res; 2001 Mar; 7(3):738-44. PubMed ID: 11297271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy and completeness in reporting family history of prostate cancer by unaffected men.
    Gaff CL; Aragona C; MacInnis RJ; Cowan R; Payne C; Giles GG; Lindeman GJ
    Urology; 2004 Jun; 63(6):1111-6. PubMed ID: 15183962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial prostate cancer in Sweden. A nationwide register cohort study.
    Grönberg H; Damber L; Damber JE
    Cancer; 1996 Jan; 77(1):138-43. PubMed ID: 8630920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age specific and attributable risks of familial prostate carcinoma from the family-cancer database.
    Hemminki K; Czene K
    Cancer; 2002 Sep; 95(6):1346-53. PubMed ID: 12216104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy.
    Cooperberg MR; Freedland SJ; Pasta DJ; Elkin EP; Presti JC; Amling CL; Terris MK; Aronson WJ; Kane CJ; Carroll PR
    Cancer; 2006 Nov; 107(10):2384-91. PubMed ID: 17039503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age specific risks of familial prostate carcinoma: a basis for screening recommendations in high risk populations.
    Grönberg H; Wiklund F; Damber JE
    Cancer; 1999 Aug; 86(3):477-83. PubMed ID: 10430256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
    Ulmert D; Serio AM; O'Brien MF; Becker C; Eastham JA; Scardino PT; Björk T; Berglund G; Vickers AJ; Lilja H
    J Clin Oncol; 2008 Feb; 26(6):835-41. PubMed ID: 18281654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cohort study of cancer risk in relation to family histories of cancer in the Utah population database.
    Kerber RA; O'Brien E
    Cancer; 2005 May; 103(9):1906-15. PubMed ID: 15779016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.